Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to $357000.0.

  • AtriCure's Gains from Investment Securities rose 46666.67% to $357000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 6260.41%. This contributed to the annual value of $7.0 million for FY2024, which is 600.88% up from last year.
  • Per AtriCure's latest filing, its Gains from Investment Securities stood at $357000.0 for Q3 2025, which was up 46666.67% from $406000.0 recorded in Q2 2025.
  • AtriCure's Gains from Investment Securities' 5-year high stood at $15.1 million during Q1 2021, with a 5-year trough of -$189.9 million in Q3 2021.
  • In the last 5 years, AtriCure's Gains from Investment Securities had a median value of $406000.0 in 2025 and averaged -$8.1 million.
  • In the last 5 years, AtriCure's Gains from Investment Securities plummeted by 9900625.0% in 2021 and then soared by 46666.67% in 2025.
  • Quarter analysis of 5 years shows AtriCure's Gains from Investment Securities stood at -$189.9 million in 2021, then surged by 100.03% to $65000.0 in 2022, then increased by 29.23% to $84000.0 in 2023, then soared by 128.57% to $192000.0 in 2024, then skyrocketed by 85.94% to $357000.0 in 2025.
  • Its last three reported values are $357000.0 in Q3 2025, $406000.0 for Q2 2025, and $10.2 million during Q1 2025.